Share LinkedIn Email Copy Link Nearly two weeks ahead of its target action date, the regulator on Wednesday has signed off on Incyte and Syndax’s Niktimvo for the third-line treatment of graft-versus-host disease.Read more about this post on Biospace
EndPoints Pfizer ends work on Sangamo’s hemophilia gene therapy, crushing biotech’s hopesDecember 31, 2024
EndPoints Despite mixed data in Alzheimer’s agitation, Axsome will still seek FDA approvalDecember 30, 2024